CNS Pharmaceuticals (CNSP) vs Traws Pharma (TRAW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CNS Pharmaceuticals is the larger company by market cap ($7.8 million vs $6.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNSP | TRAW |
|---|---|---|
| Share price | $5.34 | $0.4408 |
| Market cap | $7.80M | $6.77M |
| 1-day change | -0.19% | -8.21% |
| EPS (TTM) | $-17.90 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.54 | $3.27 |
| 52-week low | $1.90 | $0.43 |
| Distance from 52-week high | -49.34% | -86.52% |
| Analyst consensus | none | none |
| Avg. price target upside | +87.27% | +126.86% |
| Average volume | 6.40K | 569.02K |
| Shares outstanding | 1.46M | 15.37M |
| Employees | 8 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CNS Pharmaceuticals
CNSP stock →CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Traws Pharma
TRAW stock →Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
CNSP vs TRAW FAQ
Which is bigger, CNS Pharmaceuticals or Traws Pharma?
CNS Pharmaceuticals (CNSP) is larger, with a market capitalization of $7.80M compared with $6.77M for Traws Pharma (TRAW).
Are CNS Pharmaceuticals and Traws Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.